AXONE PHARMA has been active since 2010 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €8.1m and a net result of €1.6m. Equity is growing by about 3.9% per year across the filed financial years. Its solvency ranks better than 55% of 6,141 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).